Evotec SE (EVO) Research & Development (2009 - 2025)
Evotec SE (EVO) reported Research & Development of $43.7 million for Q4 2025, down 19.66% on a YoY basis from $54.4 million in Q4 2024, and up 429065.53% sequentially from -$10186.0 in Q3 2025.
Evotec SE (EVO) Research & Development (2009 - 2025) Analysis & Trends
Evotec SE (EVO) has 9 years of Research & Development data on file, last reported at $43.7 million in Q4 2025.
- For the quarter ending Q4 2025, Research & Development fell 19.66% year-over-year to $43.7 million; the trailing twelve-month figure through Dec 2025 stood at $98.1 million (down 23.5% YoY), and the FY2025 full-year result was $43.7 million, down 19.66% from the prior year.
- Research & Development improved to $43.7 million in Q4 2025, from -$10186.0 in the prior quarter.
- In the past five years, Research & Development ranged from a high of $82.5 million in Q4 2021 to a low of -$22267.1 in Q1 2021.
- A 5-year average of $22.2 million and a median of $18634.9 in 2022 frame the typical range for Research & Development.
- Across the five-year window, Research & Development plunged 168.44% in 2024 and gained 21.89% in 2025, its largest moves.
- Tracing EVO's Research & Development over 5 years: stood at $82.5 million in 2021, then declined by 5.33% to $78.1 million in 2022, then decreased by 5.57% to $73.8 million in 2023, then dropped by 26.29% to $54.4 million in 2024, then retreated by 19.66% to $43.7 million in 2025.
- Business Quant data shows EVO's Research & Development at $43.7 million in Q4 2025, -$10186.0 in Q3 2025, and $54.4 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 696.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 180.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 7.37 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 138.20 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 248.60 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 296.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 97.00 Mn |
| 10 | Evotec SE | 351.60 Mn | 351.08 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 43.69 Mn |
| Sep 30, 2025 | -10,185.98 |
| Dec 31, 2024 | 54.39 Mn |
| Sep 30, 2024 | -13,040.26 |
| Dec 31, 2023 | 73.79 Mn |
| Sep 30, 2023 | 19,053.60 |
| Jun 30, 2023 | -20,129.86 |
| Dec 31, 2022 | 78.14 Mn |
| Sep 30, 2022 | 18,634.93 |
| Jun 30, 2022 | -19,980.64 |
| Mar 31, 2022 | -20,328.90 |
| Dec 31, 2021 | 82.53 Mn |
| Sep 30, 2021 | 21,271.98 |
| Jun 30, 2021 | -20,441.30 |
| Mar 31, 2021 | -22,267.12 |
| Dec 31, 2020 | 76.19 Mn |
| Sep 30, 2020 | 19,017.47 |
| Dec 31, 2019 | 64.67 Mn |
| Sep 30, 2010 | 1,611.51 |
| Jun 30, 2010 | 1,520.88 |